Is BPC‑157 safe and effective for treating gastrointestinal conditions such as gastric ulcers or inflammatory bowel disease?

BPC-157 Should Not Be Used for Gastrointestinal Conditions Outside of Research Settings

BPC-157 is not approved by the FDA or any major regulatory authority for treating gastric ulcers or inflammatory bowel disease, and there is insufficient evidence to recommend its use outside of clinical trials or specialist research centers. While preclinical animal studies show promise, the absence of adequate human clinical data, lack of regulatory approval, and concerns about safety monitoring make it inappropriate for routine clinical use.

Evidence-Based Treatment Recommendations

For Gastric Ulcers and Peptic Ulcer Disease

Established first-line therapies include:

• Proton pump inhibitors (PPIs) remain the standard of care 1
• Potassium-competitive acid blockers (P-CABs) like vonoprazan demonstrate noninferiority to PPIs for gastric ulcer healing (94% vs 94% at 8 weeks) but are not recommended as first-line therapy due to higher costs and limited long-term safety data 1
• For H. pylori-associated ulcers, eradication therapy with P-CABs shows superior efficacy (92% vs 80% eradication rates) 1

For Inflammatory Bowel Disease (IBD)

Ulcerative Colitis:

• Mild to moderate disease: High-dose mesalazine (4g daily), topical 5-ASA therapy 2
• Moderate to severe disease: Prednisolone 40mg daily, with biologic agents (infliximab, vedolizumab) for steroid-refractory cases 2, 3
• There is insufficient evidence to recommend other agents outside clinical trials or specialist centers 4

Crohn's Disease:

• Active ileocolonic disease: High-dose mesalazine, corticosteroids, or nutritional therapy tailored to disease severity 4
• Fistulating disease: Metronidazole and/or ciprofloxacin as first-line, with azathioprine or infliximab for refractory cases 4
• Guidelines explicitly state insufficient evidence for other agents outside trials 4

Why BPC-157 Cannot Be Recommended

Lack of Human Clinical Evidence

The available evidence consists primarily of animal studies 5, 6, 7, 8, 9, 10. While BPC-157 showed protective effects in rat models of gastric ulcers (45.7-65.6% inhibition of ulcer formation) 7 and healing of various fistulas 8, only Phase II clinical trials in ulcerative colitis have been conducted, with no published results demonstrating efficacy in humans 5, 6.

Regulatory Status

• Not FDA-approved for any indication 11
• No approval from other major global regulatory authorities 11
• Temporarily banned by WADA in 2022 (though not currently listed) 11
• The FDA drug label provided 12 is for levonorgestrel (emergency contraception), not BPC-157, indicating no legitimate FDA-approved formulation exists

Safety Concerns

While animal studies report "no toxicity" and "LD1 not achieved" 5, 6, 10, comprehensive human safety data are absent. Long-term safety, drug interactions, and adverse effects in humans remain unknown 11.

Clinical Practice Implications

What to Tell Patients

Patients inquiring about BPC-157 should be informed that:

1. It is not approved for medical use
2. Human clinical data are insufficient to establish safety or efficacy
3. Proven, evidence-based treatments are available for their condition
4. Use of unregulated compounds carries unknown risks

Appropriate Treatment Algorithm

For patients with gastrointestinal conditions:

Step 1: Establish accurate diagnosis through endoscopy, imaging, and laboratory testing

Step 2: Initiate guideline-concordant therapy:

• Gastric ulcers: PPIs with H. pylori testing/treatment
• Ulcerative colitis: 5-ASA therapy ± corticosteroids based on severity
• Crohn's disease: Corticosteroids, immunomodulators, or biologics based on location and severity

Step 3: For treatment failures, escalate to advanced therapies (biologics, JAK inhibitors, S1P modulators) with established efficacy 2, 13, 3

Step 4: Consider enrollment in clinical trials for investigational agents only after standard therapies have been optimized

Important Caveats

The British Society of Gastroenterology explicitly states there is no place for unproven therapies in IBD management outside clinical trial settings 14. This principle extends to BPC-157, which lacks the rigorous human testing required for clinical recommendation.

The animal research showing wound healing, fistula closure, and anti-inflammatory effects 5, 6, 8, 9, 10 is insufficient to extrapolate to human use, as many promising preclinical compounds fail to demonstrate efficacy or safety in human trials.

Patients using BPC-157 obtained through unregulated sources face additional risks: unknown purity, contamination, incorrect dosing, and lack of medical oversight for adverse effects.